CALCA and erythema multiforme: BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy in preventing episodic migraine (EM) in 3-month studies; this analysis evaluates its long-term effects.